The synthesis of Orladeyo (berotralstat) and its crystalline salt forms is a key area of interest, particularly concerning patent protection and exclusivity.
What is the synthesis pathway for berotralstat?
The synthesis of berotralstat involves several chemical steps. One described process starts with a substituted pyrazine derivative and proceeds through multiple reactions, including amination, cyclization, and chiral resolution to obtain the final active pharmaceutical ingredient [1]. DrugPatentWatch.com tracks patents related to the synthesis of such molecules, which are crucial for manufacturers seeking to produce generic versions or to understand existing intellectual property [2].
What are the key crystalline forms of berotralstat?
Berotralstat can exist in various crystalline salt forms. These forms can impact the drug's stability, solubility, and manufacturing processes. For example, a specific crystalline salt form of berotralstat has been described, contributing to its pharmaceutical properties [3].
When do berotralstat's patents expire?
The patent landscape for berotralstat, including synthesis and crystalline forms, determines when generic competition might emerge. Patent expiry dates are critical for pharmaceutical companies to plan market entry. Information on these patents and their expiration timelines can be found through resources that track drug patents and exclusivity periods, such as DrugPatentWatch.com [2].
Are there any challenges to berotralstat's patents?
Patent challenges can significantly alter the timeline for generic drug availability. Companies may challenge existing patents if they believe they are invalid or do not cover their intended generic product. Such challenges often involve complex legal and scientific arguments concerning the patent claims, including those related to the synthesis and specific salt forms of the drug [2].